Dotmatics, Compugen sign licensing deal

By The Science Advisory Board staff writers

March 3, 2021 -- Dotmatics has signed a licensing deal that grants Compugen rights to its informatics software.

Under the multiyear agreement, Compugen scientists based at the company's research and development facility in Israel will have access to a single information management platform. The tools enable gathering, analyzing, and visualizing project data.

Compugen will have access to Dotmatics' software as a service (SaaS) technology including bioregister, inventory, studies notebook, and platform applications, which may contribute to identifying novel immuno-oncology drug targets and biomarkers.

Dotmatrics technology will replace Compugen's current laboratory information management system (LIMS) and electronic lab notebook (ELN).

Compugen, AstraZeneca reach 1st milestone in deal
Compugen announced it is entitled to receive $2 million upon reaching the first preclinical milestone in an ongoing license agreement with AstraZeneca...
Modest Growth for Lab Automation
Lab automation refers to a collection of technologies that are involved in making faster and more efficient repetitive laboratory tasks. Lab automation...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter